Emerging as a significant advance in the battle against obesity, the drug is generating considerable buzz. It combines effects of two established GLP-1 receptor agonists, semaglutide , plus an new glucose-dependent hormonal component. Early patient findings have demonstrated significant weight reduction in people with a high BMI , potentially provi